細胞程序死亡配體1(PDL1)Ki-67在上泌尿道上皮癌的預測角色
蔡牧堯1、陳建旭1、江博暉1、黃純真2
高雄長庚紀念醫院 外科部 泌尿科1;高雄長庚紀念醫院 病理科2
The role of PD-L1 and Ki-67 in Upper tract urothelial carcinoma
Mu-Yao Tsai1, Chien-Hsu Chen1, Po-Huei Chiang1, Shun-Chen Huang2
Divisions of Urology, Department of Surgery, Chang Gung Memorial Hospital, Kaohsiung, Taiwan; Department of pathology2, Chang Gung Memorial Hospital, Kaohsiung, Taiwan
 
Purpose: To evaluate programmed death-ligand 1 (PD-L1) and Ki-67 expression in UTUC in Taiwan and to survey prognostic value of PD- L1 expression and Ki-67 expression in upper tract urothelial carcinoma varies according to clinicopathologic parameters.
Materials and Methods: 501 cases of UTUC from 2013 to 2018 were retrospectively evaluated from the surgical pathology database at a single medical center. The cohort included 102 cases:  11 low-grade, 91 high-grade and pathologic 25 pTa/is, 16 pT1, 21 pT2, 32 pT3 and 8 pT4. PD-L1 immunohistochemistry (IHC) was performed on representative whole tumor sections using 22C3 anti-PD-L1. Combined positive score of tumor and immune cells was reported. We also conducted Ki-67 immunohistochemical stains.
Results: Totally 17.1 %(18 cases) of primary UTUC demonstrated positive (≥10) PD-L1 expression. Besides, there are 72 cases showed Ki-67 ≥ 10% and 49 cases Ki-67≥20% .CPS ≥ 10, Age, Distant metastasis were associated with poor cancer-specific suvrival while CPS ≥ 10, Age, T4, Distant metastasis were poor prognosticators of overall survival.
Conclusions: Ki-67 is not a good prognostic factor in this study. Positive PD-L1 expression highlights the impact of overall survival and provides a rational basis for further investigation.
    位置
    資料夾名稱
    摘要
    發表人
    TUA秘書處
    單位
    台灣泌尿科醫學會
    建立
    2020-12-23 13:58:52
    最近修訂
    2020-12-24 14:03:04
    瀏覽
    137
    1. 1.
      Podium 01
    2. 2.
      Podium 02
    3. 3.
      Podium 03
    4. 4.
      Moderated Poster 01
    5. 5.
      Moderated Poster 02
    6. 6.
      Moderated Poster 03
    7. 7.
      Non-Discussion Poster